Dr. Spitalnik on Goals for the Hemanext® Blood Storage System in Hematologic Malignancies

Video

In Partnership With:

Steven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies. 

Steven L. Spitalnik, MD, co-director, Laboratory of Transfusion Biology, professor, Pathology and Cell Biology, vice-chairman, Laboratory Medicine, Columbia University Medical Center, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies. 

The goal of the Hemanext® blood storage system is to further the understanding of red blood cell storage biology and platelet transfusions, and hopefully produce a product that better serves patients, according to Spitalnik. Moreover, developing a better understanding of the dosing and activity of red blood cells may result in better outcomes for patients, Spitalnik adds.

Current data on this blood storage technology suggest that it enables more red cells to circulate for longer periods of time, Spitalnik explains. For patients who undergo chronic transfusions, this system could lead to fewer transfusions, and a better quality of life, Spitalnik concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Ashwin Kishtagari, MD
Somedeb Ball, MBBS
Lauren E. Nye, MD
Jonathan E. Rosenberg, MD